CA3239578A1 - Peptides and methods for use in treating pain - Google Patents
Peptides and methods for use in treating pain Download PDFInfo
- Publication number
- CA3239578A1 CA3239578A1 CA3239578A CA3239578A CA3239578A1 CA 3239578 A1 CA3239578 A1 CA 3239578A1 CA 3239578 A CA3239578 A CA 3239578A CA 3239578 A CA3239578 A CA 3239578A CA 3239578 A1 CA3239578 A1 CA 3239578A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- pain
- seq
- vector
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306835.6 | 2021-12-17 | ||
| EP21306835 | 2021-12-17 | ||
| PCT/EP2022/086559 WO2023111348A1 (en) | 2021-12-17 | 2022-12-19 | Peptides and methods for use in treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3239578A1 true CA3239578A1 (en) | 2023-06-22 |
Family
ID=79317102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3239578A Pending CA3239578A1 (en) | 2021-12-17 | 2022-12-19 | Peptides and methods for use in treating pain |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250051395A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4447991A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024547029A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126864A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118401249A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129864A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022413983A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3239578A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313183A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007301A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202344689A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023111348A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119985A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating wounds and inflammatory diseases |
| WO2026119983A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating pain, wounds and inflammatory diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
| EP2801369A1 (en) | 2013-05-06 | 2014-11-12 | Centre National De La Recherche Scientifique | TAFA4 compounds and uses thereof for treating pain |
| CN108699604A (zh) | 2016-03-08 | 2018-10-23 | 艾克斯-马赛大学 | 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途 |
-
2022
- 2022-12-19 CA CA3239578A patent/CA3239578A1/en active Pending
- 2022-12-19 MX MX2024007301A patent/MX2024007301A/es unknown
- 2022-12-19 US US18/719,934 patent/US20250051395A1/en active Pending
- 2022-12-19 AR ARP220103509A patent/AR129864A1/es unknown
- 2022-12-19 IL IL313183A patent/IL313183A/en unknown
- 2022-12-19 WO PCT/EP2022/086559 patent/WO2023111348A1/en not_active Ceased
- 2022-12-19 JP JP2024536410A patent/JP2024547029A/ja active Pending
- 2022-12-19 AU AU2022413983A patent/AU2022413983A1/en active Pending
- 2022-12-19 CN CN202280083300.3A patent/CN118401249A/zh active Pending
- 2022-12-19 KR KR1020247023481A patent/KR20240126864A/ko active Pending
- 2022-12-19 TW TW111148815A patent/TW202344689A/zh unknown
- 2022-12-19 EP EP22840601.3A patent/EP4447991A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202344689A (zh) | 2023-11-16 |
| JP2024547029A (ja) | 2024-12-26 |
| AU2022413983A1 (en) | 2024-06-13 |
| KR20240126864A (ko) | 2024-08-21 |
| MX2024007301A (es) | 2024-06-26 |
| CN118401249A (zh) | 2024-07-26 |
| AR129864A1 (es) | 2024-10-09 |
| US20250051395A1 (en) | 2025-02-13 |
| EP4447991A1 (en) | 2024-10-23 |
| WO2023111348A1 (en) | 2023-06-22 |
| IL313183A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250051395A1 (en) | Peptides and methods for use in treating pain | |
| JP3474190B2 (ja) | 合成ポリヌクレオチド | |
| US20250213654A1 (en) | Peptides and methods for use in treating pain | |
| AU2019314383A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| AU2019304569B2 (en) | Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms | |
| JP7380670B2 (ja) | Igf-1-暗号化dna作製物及びhgf-暗号化dna作製物を用いた神経病症治療 | |
| JP2024527742A (ja) | アデノ随伴ウイルス粒子及びその使用方法 | |
| RU2597789C2 (ru) | Анальгетическое средство на основе плазмидной днк, кодирующей hnp-1, либо hnp-2, либо hnp-3 (варианты) | |
| OA22140A (en) | Peptides and methods for use in treating pain. | |
| JP2019070001A (ja) | 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物 | |
| KR20200074167A (ko) | 가바펜티노이드로부터의 간섭이 감소되고 hgf 이형체들을 발현하는 dna 컨스트럭트를 이용하는 신경병증의 치료 | |
| OA22072A (en) | Peptides and methods for use in treating pain. | |
| CN107075501B (zh) | 炎症报道系统 | |
| WO2021010303A1 (ja) | 顕性型変異遺伝子に由来する疾患の治療剤 | |
| CN116672435A (zh) | LRP1-β链短肽在治疗胰岛素抵抗和糖尿病中的应用 | |
| CN117003854A (zh) | 用于预防或治疗骨关节炎的蛋白组合物、mRNA组合物及用途 | |
| CN110904046B (zh) | Islr基因在制备治疗肥胖及改善胰岛素抵抗的药物中的应用 | |
| KR20130126549A (ko) | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 | |
| US20250194571A1 (en) | Compositions and methods for defining optimal treatment timeframes in lysosomal disease | |
| US20250313643A1 (en) | Humanized non-opioid composition and therapies for pain management | |
| WO2015134833A2 (en) | Therapeutic proteins for treating cancers and methods for using such proteins | |
| CN121693571A (zh) | 用于治疗中枢神经系统蛋白质病的重组腺相关病毒载体 | |
| Xu | The Effect of Neonatal Administration of Recombinant Myostatin Propeptide on Skeletal Muscle Growth in Mice. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241022 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251125 |